Resona Asset Management Co. Ltd. Takes Position in Johnson & Johnson (NYSE:JNJ)

Resona Asset Management Co. Ltd. bought a new position in shares of Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 811,447 shares of the company’s stock, valued at approximately $117,401,000. Johnson & Johnson makes up about 0.7% of Resona Asset Management Co. Ltd.’s investment portfolio, making the stock its 20th biggest position.

Several other large investors also recently bought and sold shares of JNJ. Islay Capital Management LLC grew its holdings in Johnson & Johnson by 2.6% during the 4th quarter. Islay Capital Management LLC now owns 9,247 shares of the company’s stock worth $1,337,000 after acquiring an additional 235 shares in the last quarter. AllGen Financial Advisors Inc. grew its stake in shares of Johnson & Johnson by 1.8% during the fourth quarter. AllGen Financial Advisors Inc. now owns 39,140 shares of the company’s stock worth $5,660,000 after purchasing an additional 696 shares in the last quarter. PAX Financial Group LLC increased its holdings in Johnson & Johnson by 2.3% in the fourth quarter. PAX Financial Group LLC now owns 4,492 shares of the company’s stock valued at $650,000 after buying an additional 103 shares during the last quarter. Conquis Financial LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at $33,000. Finally, Resolute Advisors LLC lifted its holdings in Johnson & Johnson by 76.2% during the 4th quarter. Resolute Advisors LLC now owns 2,363 shares of the company’s stock worth $342,000 after buying an additional 1,022 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on JNJ shares. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Barclays boosted their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Stock Down 4.3 %

JNJ stock opened at $153.03 on Friday. The stock has a market capitalization of $368.77 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company has a fifty day moving average of $159.75 and a 200-day moving average of $155.91. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.29 EPS. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.